Syndax Pharmaceuticals, Inc. · NASDAQ:SNDX
Syndax Pharmaceuticals — Q1 2026 Earnings Presentation
18 slides from Syndax Pharmaceuticals's earnings presentation, Apr 30, 2026
Slide 1: First Quarter 2026 Financial Results and Business Update
First Quarter 2026 Financial Results and Business Update April 30, 2026 Exhibit 99.2
Slide 2: Forward-looking statements disclosure
Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referenci
Slide 3: Strong 1Q26 results with multiple drivers for continued growth
$49M Revuforj net revenue in 1Q26, highlighting leadership in menin inhibition $55M Niktimvo net revenue in 1Q26, resulting in $16M in collaboration revenue $65M in total revenue to Syndax in 1Q26, up 224% vs. 1Q25 Positioned to be 1st to frontline (1L) AML with a menin inhibitor Major presence plan
Slide 4: 1Q26 Revuforj results highlight leadership in menin inhibition
1Q26 Revuforj results highlight leadership in menin inhibition and growing use in R/R NPM1m AML TRx, total prescriptions; HSCT, hematopoietic stem cell transplant; Tx, treatment EXCEPTIONAL LAUNCH >$180M net revenue ~1,380 patients treated Cumulative since launch in Nov ‘24: 1Q26 Revuforj results $4
Slide 5: Revuforj is positioned for success with an outstanding commercial foundation
Revuforj is positioned for success with an outstanding commercial foundation All covered lives includes all commercially covered lives plus Medicare and Medicaid lives. Excellent payer coverage with no meaningful barriers to access of all covered lives with formulary coverage for both Revuforj indic
Slide 6: Evolving clinical practice will drive continued Revuforj growth in 2026
Evolving clinical practice will drive continued Revuforj growth in 2026 1 2 Robust transplant rate in KMT2Ar and usage post-transplant Growing adoption in R/R NPM1m AML 3 patient population Tx durations Nearly 50% of KMT2A patients proceed to HSCT and ~45% have resumed Tx thus far R/R, relapsed/refr
Slide 7: Current Revuforj indications unlock $2B+ TAM in R/R acute leukemia
Current Revuforj indications unlock $2B+ TAM in R/R acute leukemia With the largest addressable population and anticipated duration of therapy, Revuforj is poised to become the largest targeted AML therapy R/R acute leukemia with KMT2A translocation R/R AML with NPM1m 1L “Unfit” AML with KMT2Ar or N
Slide 8: Niktimvo delivered strong 1Q26 results driven by robust demand
Building off an excellent first year, Niktimvo delivered strong 1Q26 results driven by robust demand ~300 1Q26 new patient starts ~5,000 1Q26 infusions administered Syndax records 50% of the Niktimvo net commercial profit, defined as net revenue (recorded by Incyte) minus the cost of sales and comme
Slide 9: Multiple drivers support continued Niktimvo growth in 2026
Multiple drivers support continued Niktimvo growth in 2026 1 Continued adoption in 4L and growing usage in 3L cGVHD 2 Potential for extended treatment durations to address chronic disease Broad and growing prescriber base & strong commercial synergies 3 3L, third line; 4L, fourth line; BMT, bone mar
Slide 10: Initial Niktimvo indication represents a $2B U.S. market opportunity
Initial Niktimvo indication represents a $2B U.S. market opportunity, with substantial opportunities for label and geographic expansion cGVHD, chronic graft-versus-host disease; 1. Internal data on file; 2. SmartImmunology Insights cGVHD report March 2020; 3. SmartImmunology Insights IPF report Marc
Slide 11: Revumenib (select trials): focused on unlocking full potential
Revumenib (select trials) Ph 1 Ph 2 Ph 3 FDA Approved Setting Study Name Regimen NPM1m KMT2Ar NUP98r R/R AUGMENT-101 Rev mono ● ● AUGMENT-102 Rev + IC ● ● ● SAVE Rev + ven/oral HMA ● ● ● Borate study Rev + gilt in FLT3 co-mutated ● ● ● Post-HSCT Maintenance Ball study Rev mono ● ● 1L Unfit for IC BE
Slide 12: Axatilimab (select trials)
Axatilimab (select trials) Ph 1 Ph 2 Ph 3 FDA Approved Setting Study Name Regimen R/R cGVHD AGAVE-201 Axatilimab (axa) monotherapy 1L cGVHD AXemplify-357* Axatilimab + corticosteroids NCT06388564* Axatilimab + ruxolitinib IPF MAXPIRe Axatilimab on top of SOC Robust clinical development plan underway
Slide 13: CSF1-dependent monocyte-derived alveolar macrophages as a new target in IPF
A growing body of evidence points to CSF1-dependent monocyte-derived alveolar macrophages as a promising new target in IPF Key discoveries: Monocyte-derived alveolar macrophages drive lung fibrosis Colony stimulating factor-1 receptor (CSF1R) signaling is a key regulator of monocytes and macrophages
Slide 14: Development in IPF supported by lung responses observed in cGVHD
Development in IPF supported by lung responses observed in cGVHD Axatilimab is a CSF1R-blocking antibody targeting monocyte-derived alveolar macrophages in IPF Blocking CSF-1R with axatilimab: Reduces levels of circulating profibrotic and proinflammatory monocytes and monocyte-derived macrophages In
Slide 15: Topline data from MAXPIRe Phase 2 trial of axatilimab in IPF anticipated in 4Q26
Topline data from MAXPIRe Phase 2 trial of axatilimab in IPF anticipated in 4Q26 A randomized, double-blind, placebo-controlled, multi-center international trial Key eligibility criteria: ≥40 yrs of age HRCT confirming IPF diagnosis FVC ≥45% of predicted normal (PN) FEV1/FVC ≥0.7 DLCO ≥30% and ≤90%
Slide 16: Strong financial position driven by growing revenue and stable expense outlook
Strong financial position driven by growing revenue and stable expense outlook Financial Summary ($ in millions) Three Months Ended March 31 2026 2025 Product revenue, net 48.9 20.0 Collaboration revenue, net 15.9 — Total revenues 64.9 20.0 Cost of product sales (2.6) (0.9) Research & development (R
Slide 17: 2026 anticipated milestones and 2025 key accomplishments
Continued focus on driving revenue growth and pipeline progress, with another data-rich year ahead 2026 Anticipated Milestones 2025 Key Accomplishments Advance global enrollment in pivotal 1L trials of revumenib Advance leadership in menin inhibition with new 1L, maintenance, R/R, and real-world evi
Slide 18: Slide 18
Syndax Pharmaceuticals — Q1 2026 Earnings Presentation on 6ix